|
SLEDAI-2 k (points); median (range)
|
8 (2 to 14)
|
11 (0 to 16)
|
9 (3 to 18)
|
|
gender female number (%)
|
18 (72.0)
|
14 (70.0)
|
18 (81.8)
|
|
age (years); mean ± SD
|
38 ± 13
|
34 ± 9
|
40 ± 14
|
|
duration (years); median (range)
|
9 (2 to 28)a
|
4 (0 to 25)a
|
10 (0 to 26)
|
|
age at initial diagnosis of SLE (years); mean ± SD
|
27 ± 11
|
29 ± 10
|
29 ± 14
|
|
medication
| |
|
prednisone (mg/day); median (range)
|
7.0 (2.5 to 15.0)
|
10.0 (0.0 to 30.0)
|
6.3 (0.0 to 100.0)
|
|
co-medication with antimalarials number (%)
|
18 (72.0)
|
12 (60.0)
|
16 (72.7)
|
|
currently active manifestations number (%)
| |
|
class III-V nephritis
|
10 (40.0)
|
12 (60.0)
|
6 (27.3)
|
|
eGFR <60 ml/min
|
7 (28.0)
|
4 (20.0)
|
3 (13.6)
|
|
C3c <0.9 g/L
|
18 (72.0)
|
14 (70.0)
|
16 (72.7)
|
|
neuropsychiatric
|
0
|
0
|
0
|
|
mucocutaneous/cutaneous
|
8 (32.0)
|
8 (40.0)
|
7 (31.8)
|
|
arthritis
|
5 (20.0)
|
0bb
|
9 (40.9)bb
|
|
serositis
|
1 (4.0)
|
0
|
4 (18.2)
|
|
myositis
|
1 (4.0)
|
1 (5.0)
|
1 (4.5)
|
|
autoantibodies number (%)
| |
|
anti-dsDNA >7 U/ml
|
21 (84.0)
|
15 (75.0)
|
20 (90.9)
|
|
anti-Ro >7 U/ml
|
11 (44.0)
|
10 (50.0)
|
13 (59.1)
|
|
anti-La >7 U/ml
|
4 (16.0)
|
4 (20.0)
|
4 (18.2)
|
|
anti-U1-RNP >5 U/ml
|
11 (44.0)
|
12 (60.0)
|
8 (36.4)
|
|
anti-SM >5 U/ml
|
7 (28.0)
|
9 (45.0)
|
4 (18.2)
|
